MACROGENICS INC
MGNXNasdaq
$4.49
↑ +9.0%Jul 17 close · end-of-day
Price
1Y↑ +195.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$284.9M
Enterprise Value
$218.4M
P/E
—
P/S
1.8
P/B
13.4
EV/EBITDA
—
PEG
—
FCF Yield
-25.2%
Dividend Yield
—
Revenue (TTM)
$157.1M
Net Income (TTM)
$4.2M
Free Cash Flow (TTM)
-$71.7M
Gross Margin
—
Operating Margin
-40.5%
Net Margin
2.7%
ROE
19.8%
ROIC
—
Debt / Equity
—
Net Cash
$66.5M
Return 1Y
+191.6%
Company profile
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer. The company also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4.
- CEO
- Scott E. Koenig
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 430
- Headquarters
- Maryland
- Website
- macrogenics.com
Management & directors
- Bonvini EzioSr VP, Research & CSO
- Karrels JamesSVP and CFO
- Peters Jeffrey StuartSenior VP, GC, and Secretary
- Risser Eric BlasiusPresident and CEO
- Smith Beth AnnVP, Controller & Treasurer
- Spitznagel ThomasSr VP, Technical Ops
Roles derived from SEC Form 4 filings.
Earnings
MGNX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$20.8M↑ +57.5%
Diluted EPS-$0.58↓ -10.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $104.9M | $77.4M | $151.9M | $58.7M | $150.0M | $149.5M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$131.1M | -$202.8M | -$121.4M | -$168.2M | -$110.6M | -$72.8M |
| Net income | -$129.7M | -$202.1M | -$119.8M | -$9,058.00 | -$66,966.00 | -$74,620.00 |
| Diluted EPS | -$2.47 | -$3.37 | -$1.95 | -$0.15 | -$1.07 | -$1.18 |
| Operating cash flow | -$111.9M | -$143.8M | -$87.0M | -$78.2M | -$68.4M | -$81.0M |
| Free cash flow | -$117.8M | -$150.0M | -$90.6M | -$80.0M | -$72.1M | -$83.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -125.0% | -261.9% | -79.9% | -286.4% | -73.7% | -48.7% |
| Net margin | -123.7% | -261.0% | -78.8% | -0.0% | -0.0% | -0.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.8M | $110.7M | $19.4M | $13.2M | $22.2M | $72.8M | $41.2M | $20.8M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$58.2M | $54.2M | -$52.8M | -$42.6M | -$36.8M | $18.6M | -$12.1M | -$33.4M |
| Net income | -$55.7M | $56.3M | $51.5M | -$41.0M | -$36.3M | $16.8M | $60.4M | -$36.8M |
| Diluted EPS | -$0.89 | $0.90 | -$0.24 | -$0.65 | -$0.57 | $0.27 | -$0.23 | -$0.58 |
| Operating cash flow | -$44.5M | $60.2M | -$38.4M | -$46.9M | -$47.0M | -$30.2M | $43.0M | -$35.8M |
| Free cash flow | -$45.5M | $59.6M | -$39.0M | -$47.4M | -$47.7M | -$30.6M | $42.8M | -$36.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -538.9% | 48.9% | -273.0% | -323.1% | -165.3% | 25.6% | -29.3% | -161.0% |
| Net margin | -515.6% | 50.9% | 266.0% | -311.1% | -163.0% | 23.1% | 146.5% | -177.0% |
Company news
Jul 2, 2026
- 17d agoVERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestonefinance.yahoo.com
- 18d agoMacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?finance.yahoo.com
- 18d agoBora Pharmaceuticals Completes Acquisition of MacroGenics' Rockville Manufacturing Operationsfinance.yahoo.com
- 18d agoMacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticalsfinance.yahoo.com
Jun 22, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-18 | Liu Margaret | Option exercise | 3,750 | — | — | filing |
| 2026-05-18 | O'Brien Federica F. | Option exercise | 3,750 | — | — | filing |
| 2026-05-18 | Chhabra Meenu | Option exercise | 3,750 | — | — | filing |
| 2026-05-18 | HURWITZ EDWARD | Option exercise | 3,750 | — | — | filing |
| 2026-05-18 | STUMP DAVID C | Option exercise | 3,750 | — | — | filing |
| 2026-05-18 | Ferrante Karen Jean | Option exercise | 3,750 | — | — | filing |
| 2026-05-18 | Jackson Scott Thomas | Option exercise | 3,750 | — | — | filing |
| 2026-05-18 | HEIDEN WILLIAM K | Option exercise | 3,750 | — | — | filing |
| 2026-05-18 | SIEGEL JAY PHILIP | Option exercise | 3,750 | — | — | filing |
| 2026-02-15 | Risser Eric Blasius· President and CEO | Tax withholding | 6,433 | $1.71 | $11,000.43 | filing |
| 2026-02-15 | Bonvini Ezio· Sr VP, Research & CSO | Tax withholding | 6,433 | $1.71 | $11,000.43 | filing |
| 2026-02-15 | Karrels James· SVP and CFO | Tax withholding | 5,790 | $1.71 | $9,900.90 | filing |
| 2026-02-15 | Spitznagel Thomas· Sr VP, Technical Ops | Tax withholding | 5,520 | $1.71 | $9,439.20 | filing |
| 2026-02-15 | Peters Jeffrey Stuart· Senior VP, GC, and Secretary | Tax withholding | 5,147 | $1.71 | $8,801.37 | filing |
| 2026-02-15 | Smith Beth Ann· VP, Controller & Treasurer | Tax withholding | 423 | $1.71 | $723.33 | filing |
| 2026-02-15 | Koenig Scott | Option exercise | 21,165 | $0.00 | $0.00 | filing |
| 2026-02-15 | Spitznagel Thomas· Sr VP, Technical Ops | Option exercise | 13,332 | — | — | filing |
| 2026-02-15 | Bonvini Ezio· Sr VP, Research & CSO | Option exercise | 16,665 | — | — | filing |
| 2026-02-15 | Smith Beth Ann· VP, Controller & Treasurer | Option exercise | 1,095 | — | — | filing |
| 2026-02-15 | Karrels James· SVP and CFO | Option exercise | 14,999 | — | — | filing |
| 2026-02-15 | Peters Jeffrey Stuart· Senior VP, GC, and Secretary | Option exercise | 13,332 | — | — | filing |
| 2026-02-15 | Risser Eric Blasius· President and CEO | Option exercise | 16,665 | — | — | filing |
| 2026-02-08 | Bonvini Ezio· Sr VP, Research & CSO | Tax withholding | 4,311 | $1.81 | $7,802.91 | filing |
| 2026-02-08 | Risser Eric Blasius· President and CEO | Tax withholding | 4,311 | $1.81 | $7,802.91 | filing |
| 2026-02-08 | Karrels James· SVP and CFO | Tax withholding | 3,860 | $1.81 | $6,986.60 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.